NYSE:HIMSHealthcare
Hims & Hers Health (HIMS) Is Down 5.5% After Novo Nordisk GLP-1 Lawsuit and FDA Scrutiny
In early February 2026, Novo Nordisk filed a patent infringement lawsuit against Hims & Hers over its compounded semaglutide weight-loss products, following an FDA crackdown that also prompted Hims & Hers to abruptly halt its newly launched Compounded GLP-1 Pill.
The clash not only raises serious questions about the safety and legality of compounded GLP-1 treatments, but also directly challenges Hims & Hers' efforts to expand its weight-loss franchise as a core growth driver.
We’ll now...